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Abstract Violacein (VIO; 3-[1,2-dihydro-5-(5-hydroxy-1H-
indol-3-yl)-2-oxo-3H-pyrrol-3-ylidene]-1,3-dihydro-2H-indol-
2-one), an indole-derived purple-colored pigment, produced by
a limited number of Gram-negative bacteria species, including
Chromobacterium violaceum and Janthinobacterium lividum,
has been demonstrated to have anti-cancer activity, as it inter-
feres with survival transduction signaling pathways in different
cancer models. Head and neck carcinoma (HNC) represents the
sixth most common and one of the most fatal cancers world-
wide. We determined whether VIOwas able to inhibit head and
neck cancer cell growth both in vitro and in vivo. We provide
evidence that VIO treatment of human and mouse head and
neck cancer cell lines inhibits cell growth and induces autoph-
agy and apoptosis. In fact, VIO treatment increased PARP-1
cleavage, the Bax/Bcl-2 ratio, the inhibition of ERK1 and
ERK2 phosphorylation, and the expression of light chain 3-II
(LC3-II). Moreover, VIO was able to induce p53 degradation,
cytoplasmic nuclear factor kappa B (NF-κB) accumulation, and
reactive oxygen species (ROS) production. VIO induced a sig-
nificant increase in ROS production. VIO administration was
safe in BALB/c mice and reduced the growth of transplanted
salivary gland cancer cells (SALTO) in vivo and prolonged
median survival. Taken together, our results indicate that the
treatment of head and neck cancer cells with VIO can be useful
in inhibiting in vivo and in vitro cancer cell growth. VIO may
represent a suitable tool for the local treatment of HNC in com-
bination with standard therapies.
Keywords Violacein . Janthinobacterium lividum . Head and
neck cancer
Introduction
Violacein (VIO; 3-[1,2-dihydro-5-(5-hydroxy-1H-indol-3-yl)-
2-oxo-3H-pyrrol-3-ylidene]-1,3-dihydro-2H-indol-2-one) is an
indole-derived purple-colored pigment, produced by a limited
number of Gram-negative bacteria species, including
Chromobacterium violaceum and Janthinobacterium lividum.
The role of VIO in bacterial life and metabolism is not fully
understood. Different studies have demonstrated a potential role
for VIO in environmental competition with other microorgan-
isms, as it has anti-protozoal, anti-bacterial, and anti-Candida
activities [1–8]. These properties may play a key role in the
survival and diffusion of VIO-producing bacteria in ecological
competition with other microorganisms for nutrients. Thus,
VIO production and biofilm development may represent a re-
sponse to environmental stresses and a key factor in survival
mechanisms of J. lividum. As a consequence, VIO and biofilm
production, both under quorum-sensing regulation, could be
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considered to be beneficial factors of J. lividum resistance to
different types of environmental stress [9].
Several studies have demonstrated that VIO has anti-tumor,
anti-viral, anti-ulcerogenic, immunomodulatory, analgesic,
and anti-pyretic activities [10]. Indeed, it has been shown that
VIO induces apoptosis in HL60 leukemic cells through the
activation of caspase-8, the transcription of nuclear factor kap-
pa B (NF-κB) target genes and the activation of p38 mitogen-
activated protein (MAP) kinase and the tumor necrosis factor
alpha (TNF-α) signal transduction pathway. In addition, VIO
was shown to be non-cytotoxic in normal healthy cells [7].
The anti-tumor potential of VIO is not restricted to acute my-
eloblastic leukemia. Recent reports have demonstrated its ben-
eficial effects against BCR-ABL-positive chronic myeloid
leukemia cells (K562 cell line), including their multidrug-
resistant variant. The molecular mechanisms of VIO action
involve the activation of specific signaling transduction path-
ways, dependent on the cell type. This observation was cor-
roborated by studies performed in prostate, lung, colon cancer
cell lines and in Ehrlich’s ascites tumors [11–13]. In addition,
it has been demonstrated that VIO was highly cytotoxic for
colorectal cancer (CRC) cells [12]. VIO inhibited Akt phos-
phorylation with the subsequent reactivation of the apoptosis
pathway and downregulation of NF-κB, MDM2, p21–p27,
GSK3α/β and Bad signaling in CRC cells [13]. Recently, it
has been reported that VIO inhibited the proteolytic activity of
MMPs and downregulated CXCL12–CXCR4 interactions,
thus inhibiting cell migration and invasion in breast cancer
cell lines [14]. VIO was shown to increase the production of
reactive oxygen species (ROS), followed by the activation of
caspase-3, the release of cytochrome c, the release of calcium
from the cytosol and the induction of the collapse of the mi-
tochondrial membrane, thus leading to tumor cell apoptosis
[11].
There is limited evidence for VIO having an effect on solid
tumors, both in vitro and in vivo. Head and neck carcinoma
(HNC) represents the sixth most common cancer worldwide,
and it mainly involves the larynx, pharynx, oral cavity, and
tongue [15, 16].
The treatments for HNC have been associated with consid-
erable complications and potential treatment-related death.
Thus, although there have been significant advances in both
surgical and non-surgical therapy, the overall survival and
quality of life of patients with HNC have not been significant-
ly improved over the past decade, especially for patients in an
advanced stage. Indeed, the current strategies to cure these
tumors have limited efficacy and documented toxicity and
HNC remains one of the most fatal cancers worldwide [17].
The discovery and development of innovative drugs might
supplement the pharmaceutical armamentarium presently
used for HNC management.
Cancer chemoprevention makes use of natural or synthetic
compounds to prevent, arrest, or reverse the process of
carcinogenesis in its earliest stages [18]. Moreover, com-
pounds derived from bacteria are now being tested for their
anti-cancer activity [19, 20].
This study was aimed at determining VIO anti-tumor ac-
tivities in HNC both in vitro and in vivo. In this study, we
provide evidence that VIO inhibits proliferation and induces
autophagy and apoptosis of HNC cell lines in vitro and delays
the tumor cell growth of a salivary gland carcinoma cell line
in vivo. Elucidation of the molecular mechanism mediating
this activity provides further relevant information for under-
standing its anti-tumoral effects and for considering its possi-
ble clinical applications.
Materials and methods
Reagents
DMSO, sulforhodamine B (SRB), and Hoechst 33342 were
purchased from Sigma-Aldrich (Milan, Italy). Rabbit poly-
clonal anti-Bax and mouse monoclonal anti-Bcl-2 antibodies
were obtained from BD Pharmingen (BD Biosciences). Anti-
bodies against ERK1/2 (C-14), phospho-ERK (E-4), NF-κB,
PARP-1, and p53 (DO-1) were obtained from Santa Cruz
Biotechnology (CA, USA). Antibody against light chain 3
(LC3) was obtained from Novus Biologicals (Littleton, CO,
USA). Rabbit polyclonal anti-actin was from Sigma-Aldrich.
The anti-caspase-9 and anti-caspase-8 antibodies were pur-
chased from Cell Signaling Technology (MA, USA). Goat
anti-mouse IgG Alexa Fluor-488-conjugated antibody was
purchased from Life Technologies™ Molecular Probes (Ore-
gon, USA), and the goat anti-mouse or anti-rabbit IgG
peroxidase-conjugated secondary antibodies were from Sig-
ma-Aldrich.
Production of VIO
For VIO production and extraction, the bacterial strain
J. lividum DSM1522T was used. J. lividum was maintained
frozen in a brain–heart infusion broth (BHI; Difco Laborato-
ries, Livonia, MI, USA) containing glycerol (25 %) at −80 °C
until use. J. lividum was cultured and checked for purity on
trypticase soy agar (TSA; Oxoid Ltd., Basingstoke, UK) at
25 °C for 48 h. To obtain VIO production, J. lividum
DSM1522T was cultured in a modified Luria-Bertani (LB)
broth medium supplemented with 1 % glycerol as carbon
source (LBY) [9]. Briefly, after checking for purity on a
TSA agar plate, a single colony was taken as a pre-inoculum
in LBY maintained at 25 °C until reaching the logarithmic
phase of growth.
Pre-inoculum (1:100v/v) was used to inoculate 5 l of LBY,
distributed in culture flasks (50 cc each; Corning® Erlenmeyer
cell culture flasks with venting position), and incubated in
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static conditions at 25 °C until reaching the late stationary
phase. After 48 h of incubation, the growth medium
was removed by centrifugation, and the purple-colored
pellet of cells was re-suspended in absolute methanol
(three fourth of the initial volume), gently mixed by
hand for 15 min and then centrifuged at 13,000 rpm
for 30 min. After centrifugation, the pellet containing
cells and cell debris was discarded and the supernatant
containing the eluted pigment VIO was recovered for
further purification. To obtain a final product with fewer
impurities, we only recovered pigment from cells.
Purification of VIO
All reagents and solvents were handled according to the ma-
terial safety data sheet of the supplier and were used as pur-
chased. Macherey-Nagel silica gel pre-coated aluminum cards
with a fluorescent indicator visualizable at 254 nm were used
for thin-layer chromatography. Developed plates were visual-
ized with a Spectroline ENF-260C/FE UV apparatus. Evapo-
ration of the solvents was carried out on a Büchi Rotavapor R-
210 equipped with a Büchi V-855 vacuum controller and
Büchi V-700 (~5 mbar) and V-710 (~2 mbar) vacuum pumps.
Flash chromatography was carried out with an Interchim Spot
II Flash, using Merck SuperVarioFlash D26 cartridges packed
with Merck Geduran 60 (0.040–0.063 mm) silica gel. Melting
points (MPs) were determined using a Stuart Scientific SMP1
apparatus and are uncorrected. Infrared (IR) spectra were run
on PerkinElmer Spectrum One FT-ATR spectrophotometer.
Proton (1H, 400.13 MHz) and carbon (13C, 100.6 MHz) nu-
clear magnetic resonance spectra were recorded by a Bruker
Avance 400. 1H and 13C nuclear magnetic resonance (NMR)
data were acquired by Bruker TopSpin 2.1 software and proc-
essed by Mestrelab Research S.L. MestreReNov. 6.2.1–769
software. Chemical shifts are expressed in delta units (ppm)
with tetramethylsilane. The purity of tested compounds was
found to be >95 % by high-pressure liquid chromatography
(HPLC) analysis. The HPLC system that was used (Thermo
Fisher Scientific Inc., Dionex UltiMate 3000) comprised a
SR-3000 solvent rack, a LPG-3400SD quaternary analytical
pump, a TCC-3000SD column compartment, a DAD-3000
diode array detector, and an analytical manual injection valve
with a 20-μl loop. Samples were dissolved in acetonitrile at
1 mg/ml. HPLC analysis was performed with a Thermo Fisher
Scientific Inc., Acclaim 120 C18 reversed-phase column
(5 μm, 4.6 mm×250 mm) at 25±1 °C with an isocratic gra-
dient (acetonitrile:water=90:10), flow rate of 1.0 ml/min, and
signal detector at 254 and 365 nm. Chromatographic data
were acquired and processed by Thermo Fisher Scientific
Inc., Chromeleon 6.80 software.
The methanol extract (≈550 ml) was evaporated in vacuo,
producing a black residue (0.87 g). The crude product was
purified by flash chromatography (chloroform:ethanol as
eluent) to produce VIO as a purple solid (7.3 mg), MP>
300 °C (from methanol), and literature MP>350 °C [21]. 1H
NMR, 13C NMR, and IR spectra were identical to those re-
ported in the literature [21].
Cell lines and treatments
Cell lines derived from carcinoma of the tongue (CAL-27
and SCC-15) or pharynx (FaDu) were maintained in
RPMI containing 10 % fetal bovine serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin. MCF-10A (a
non-tumorigenic epithelial cell line) and HaCaT (a human
immortalized keratinocyte cell line) cells were maintained
in Dulbecco’s modified eagle medium (DMEM) contain-
ing 10 % fetal bovine serum, 100 U/ml penicillin, and
100 μg/ml streptomycin. For treatments, cells were incu-
bated for the indicated times in the presence of VIO (dose
range 1–15 μM) or vehicle control (DMSO≤0.1 %). Neu-
overexpressing salivary gland cancer cells (H-2d)
(SALTO) were kindly provided by Prof. F. Cavallo (Uni-
versity of Torino) and Prof. P.L. Lollini (University of
Bologna) and maintained in DMEM containing 20 % fetal
bovine serum (FBS). SALTO cells were established from
salivary carcinoma arising in BALB-neuT transgenic male
mice hemizygous for p53172R-H transgene driven by the
whey acidic protein promoter [22].
SRB assay
Cells were seeded at 4×103/well in 96-well plates and incubat-
ed at 37 °C to allow cell attachment. After 24 h, the medium
was changed and the cells were treated with VIO or with
DMSO and incubated for 24, 48, or 72 h. Cells were then fixed
with cold trichloroacetic acid (final concentration 10 %) for 1 h
at 4 °C. The assay was then performed as previously described
[23]. The percentage survival of the cultures treated with the
compounds or DMSO was calculated by normalization of their
optical density (OD) values to those of untreated control cul-
tures [23]. The experiments were performed in triplicate and
repeated three times.
Fluorescence-activated cell sorting analysis
Asynchronized log phase growing cells (60 % confluent, ap-
proximately 2.5×105/well in 6-well plates) were treated with
VIO or with DMSO in complete culture medium. After 48 h,
adherent as well as suspended cells were harvested, centri-
fuged at 1500 rpm for 10 min and washed twice with cold
phosphate-buffered saline (PBS). The assay was then per-
formed as previously described [24]. Cells were analyzed by
flow cytometry using a fluorescence-activated cell sorting
(FACS) Calibur cytometer running CellQuest software.
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Western blotting
Briefly, 1×106 cells were seeded in 100-mm tissue culture
dishes 24 h prior to the addition of 5 or 7.5 μM of VIO or
DMSO. After 24 h of treatment, the cells were harvested,
washed twice with cold PBS, and lysed in RIPA buffer, as
previously described [24]. For immunoblotting analysis,
50–80 μg of cell lysates were resolved by SDS-PAGE
and then transferred to nitrocellulose membranes. Equal
loading and transfer of proteins were verified by
Ponceau red staining of the filters and actin immuno-
staining. The assay was then performed as previously
described [24].
Fluorescent measurement of ROS
Dichlorofluorescin diacetate (DCF-DA) was used to detect
ROS production in cells. Briefly, 2.5×105 cells were seeded
into 6-well plates and incubated at 37 °C to allow cell attach-
ment before treatment. After two washings with PBS, cells
were incubated with 10 μM 2′,7′-dichlorofluoresce in
diacetate (Sigma-Aldrich, Milan, Italy) in PBS at 37 °C and
5%CO2 in the dark for 30min [25]. After two washings, cells
were treated with VIO in serum-free medium and incubated at
37 °C and 5 % CO2 in the dark for different times (15 min–
4 h). Then, adherent cells and suspended cells were harvested,
centrifuged at 1250 rpm for 10 min, and seeded in 96-well
plates (100 μl per well). Fluorescence intensity was measured
after 15 and 30 min and 1 and 4 h using a spectrophotometric
plate reader at an excitation wavelength of 495 nm and an
emission wavelength of 535 nm. Because the highest level
of fluorescence was detected at 30 min and then decreased
back to the level of the control after 1 h of stimulation (data
not shown), this experimental time was chosen for subsequent
experiments.
Immunofluorescence
Cells were seeded (2.5×104/well) on eight-chamber
Permanox slides (Lab-Tek, IL) in 300 μl of culture medium,
grown for 24 h, and treated with VIO or with DMSO in com-
plete culture medium. After 24 h, the culture medium was
removed, and after two washes with PBS, the cells were fixed
with cold methanol at −20 °C for 10 min [26]. The cells were
then incubated at room temperature with primary antibodies
for 1 h and, after two further washes, with goat anti-mouse
IgG Alexa Fluor-488-conjugated secondary antibody for
45 min. Nuclei were counterstained with Hoechst 33342.
The slides were then mounted with glycerol, observed with
an Olympus BX51 fluorescence microscope, and analyzed
with IAS software.
Treatment of BALB/c mice with VIO
BALB/c mice were subcutaneously injected in the right flank
with a 0.2 ml suspension containing 1×106 SALTO cells in
PBS. Groups of BALB/c mice (five or six mice per group)
were treated weekly, starting 3 weeks after SALTO transplan-
tation, with an intratumoral injection of 0.75 mg/kg of VIO
dissolved in DMSO and diluted in PBS. The control group
was intratumorally injected with DMSO dissolved in PBS.
Mice were sacrificed at the first signs of distress. All exper-
iments were approved by the Institutional Animal Care andUse
Committee (IACUC) and carried out according to Italian rules
(D.L.vo 116/92 and C.E. 609/86). A veterinary surgeon was
present during the experiments. Animal care, before and after
the experiments, was carried out only by trained personnel.
Analysis of anti-tumor activity in vivo
Tumor growth was monitored weekly until tumor-bearing
mice were sacrificed when the tumor exceeded 20 mm in
width. Tumors were measured by a caliper in two dimensions,
and the volumes were calculated using the following formula:
width2×length/2 [27].
Statistical analysis
Data distribution of cell survival and FACS analyses were
preliminarily verified by the Kolmogorov-Smirnov test, and
data sets were analyzed with a one-way analysis of variance
(ANOVA) followed by a Newman-Keuls test. Survival curves
and tumor volumes were estimated using the Kaplan-Meier
method and compared with a log-rank test with calculation of
the SD according to the method of Greenwood. Differences
were regarded as significant when the p value was ≤0.05 [28].
Results
Production and purification of VIO
To produce VIO, J. lividum DSM1522Twas cultured in LBY.
Pre-inoculum (1:100v/v) was used to inoculate 5 l of LBY, and
it was incubated in static conditions at 25 °C until reaching the
late stationary phase. After 48 h of incubation, the growth
medium was removed by centrifugation and the purple-
colored pellet of cells was re-suspended in absolute methanol.
From 5 l of LBY culture of J. lividum DSM1522T, approxi-
mately 3 l of raw VIO was recovered and extracted using
absolute methanol as the solvent. The extracted VIO, quanti-
fied by a spectrophotometer (OD585=5.81), was used for sub-
sequent purification. Part of the methanol extract was evapo-
rated and purified by flash chromatography to obtain pure
VIO.
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Inhibition of human and mouse HNC cells survival
by VIO
To evaluate the effect of VIO on the survival of tongue (CAL-
27 and SCC-15) and pharynx (FaDu) carcinoma cell lines, in-
creasing concentrations (1, 2.5, 5, 10, and 15 μM) of VIO or
vehicle control (DMSO) cells were incubated for 24, 48, and
72 h. The effect of VIO on cell growth of mouse SALTO cells
was analyzed as well. The effect on cell growth was determined
with the SRB assay. As shown in Fig. 1, VIO significantly
inhibited the growth of all cancer cell lines in a dose- and
time-dependent manner. Indeed, better inhibition of cell prolif-
eration was obtained for all cell lines treated with VIO com-
pared to those treated with DMSO (p<0.001) at concentrations
of 10–15 μM and after 72 h. However, FaDu and SALTO cells
were sensitive to VIO treatment even at the lower concentra-
tions at 24 h (p<0.01 for FaDu cells treated with 1 and 2.5 μM
VIO and p<0.05 and p<0.01 for SALTO cells treated with 1
and 2.5 μM VIO, respectively; Fig. 1). The concentration of
VIO required to inhibit cell survival by 50 % (IC50) ranged
between 2.32 and 7.06 μM after 48 h of treatment (Table 1).
In addition, the survival of a human non-tumorigenic epi-
thelial cell line (MCF-10A), and of a human immortalized
keratinocyte cell line (HaCaT), upon VIO treatment was eval-
uated. It is of note that VIO had no effects on survival of
MCF-10A and HaCaT cells at the concentrations of 1–2.5 to
5–10 μM after 24, 48, or 72 h. However, VIO significantly
inhibited cells survival after 48 and 72 h at the higher dose
(15 μM) (p<0.05 and p<0.001, respectively, for MCF-10A
and p<0.01 and p<0.001, respectively, for HaCaT), thus sug-
gesting an in vitro toxic effect of the compound when used at
this concentration. However, significant differences in cell
survival between HNC and MCF-10A and HaCaT cells were
also observed at the 15 μM concentration. Differences of cells
survival between HNC and MCF-10A and HaCaT cells are
reported in Fig. 1.
VIO induces apoptosis in HNC cell lines
The effect of VIO on the cell cycle distribution in HNC and
MCF-10A cell lines was determined by flow cytometric anal-
ysis. Cells were incubated for 48 h with VIO (10 and 5 μM) or
Fig. 1 Effect of VIO on head and neck carcinoma cell line survival.
Survival of human pharynx (FaDu), tongue (CAL-27 and SCC-15), and
mouse salivary gland (SALTO) cancer cell lines and human non-
tumorigenic epithelial (MCF-10A) and immortalized keratinocyte
(HaCaT) cell lines were assessed with a SRB assay after 24, 48, or 72 h
of treatment with DMSO or VIO. The results are reported as the mean±
SD values from three experiments performed in triplicate (§p<0.05,
*p<0.01, #p<0.001 vsDMSO treatment). **Significant difference in cell
survival between HNC and MCF-10A cells, FaDu versus MCF-10A,
p<0.001(15, 10, 5, and 2.5 μM at 24 h; 15, 10, and 5 μM at 48 h; and
15–10 μM at 72 h), p<0.01 (1 μM at 24 h), and p<0.05 (5 μM at 72 h);
CAL-27 versus MCF-10A, p<0.001 (15, 10, and 5 μM at 24, 48, and
72 h) and p<0.05 (2.5 μM at 24 h); and SCC-15 versus MCF-10A,
p<0.001 (15–10 μM at 24 h and 15, 10, and 5 μM at 48 and 72 h) and
p<0.01 (5 μM at 24 h). **Significant difference in cell survival between
HNC and HaCaT cells, FaDu versus HaCaT, p<0.001 (all doses at 24 h;
15, 10, and 5 μM at 48 h; and 15–10 μM at 72 h), p<0.01 (5 μM at 72 h),
and p<0.05 (2.5–1μMat 48 h); CAL-27 versus HaCaT, p<0.001 (15, 10,
and 5 μM at 24, 48, and 72 h) and p<0.01 (2.5 μM at 24 h); and SCC-15
versus HaCaT, p<0.001 (15–10 μM at 24 h; 15, 10, and 5 μM at 48 and
72 h) and p<0.01 (5 μM at 24 h)
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with DMSO as a control (Fig. 2). The mean results of three
independent experiments are reported in Table 2.
As shown in Table 2, treatment with VIO induced a dose-
dependent increase in the percentage of cells in sub-G1 phase
(p<0.001 for FaDu, CAL-27, and SALTO and p<0.01 for
SCC-15 cells treated with 10 μM VIO) and a decrease in the
percentage of cells in the G0/G1 phase (p<0.001) in all cell
lines. In addition, a decrease in the percentage of cells in the
G2/M phase was observed in SCC-15, FaDu, and SALTO
cells (p<0.05 for SCC-15 and p<0.01 for FaDu and SALTO
cells) at the highest concentration. A simultaneous decrease in
the percentage of cells in S-phase was observed in FaDu and
SALTO cells (p<0.05 for FaDu cells treated with 10 μMVIO
and p<0.001 and p<0.01 for SALTO cells treated with 10 and
5 μM VIO, respectively), while CAL-27 showed an increase
in the percentage of cells in this phase at 5 μM (p<0.001). No
effects of VIO on the cell cycle distribution were observed in
MCF-10A cells at all doses tested (Fig. 2).
To demonstrate that the effect of VIO on the increase of cells
in sub-G1 was due to the induction of apoptosis, we analyzed
different signal transduction pathways involved in the activa-
tion of the apoptotic process.
HNC cell lines were treated with VIO (5–7.5 μM) for
24 h, and the expressions of Bax, Bcl-2, procaspase-9 and
procaspase-8, active caspase-8, PARP-1, and p53 were an-
alyzed by Western blotting. As shown in Fig. 3A, treatment
with 5 μM VIO induced an increase of the expression of
Bax (pro-apoptotic) in all lines examined and a decrease of
Bcl-2 (anti-apoptotic) in CAL-27, SCC-15, and SALTO
cells compared to DMSO-treated cells (p=0.019, p=
0.048, and p=0.045, respectively). Similar results were
obtained using 7.5 μM of VIO (p=0.042) in FaDu cells.
The increased expression of Bax and the decreased expres-
sion of Bcl-2 determined by VIO treatment shifted the cell
balance to programmed cell death.
To determine which apoptotic pathway was activated
after VIO treatment, the expressions of procaspase-9 and
procaspase-8 and caspase-8 were analyzed with Western
blotting in FaDu, CAL-27, SCC-15, and SALTO cells.
VIO reduced the level of procaspase-9 compared to DMSO
(p<0.001), thus indicating its activation [29] (Fig. 3a). In
addition, procaspase-8 was cleaved after VIO treatment.
Table 1 VIO concentrations required for 50 % inhibition of HNC cell
line survival (IC50)
HNC cell lines VIO treatment (hours) IC50 (μM)±SD
FaDu 24 5.79±0.91
48 5.29±0.83
72 5.94±0.64
CAL-27 24 6.72±0.24
48 4.13±0.22
72 4.15±0.37
SCC-15 24 8.07±0.18
48 7.06±0.49
72 4.65±1.15
SALTO 24 6.88±0.64
48 2.32±0.7
72 2.48±0.05
Fig. 2 Effect of VIO on cell cycle distribution. FACS analysis of DNA content was performed on asynchronized log phase growing HNC and MCF-
10A cells treated for 48 h with DMSO or VIO at 5 and 10 μM. A representative experiment is shown in the figure
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Treatment with VIO at a concentration of 5 μM (CAL-27,
SCC-15, and SALTO) or 7.5μM (FaDu) was able to induce the
proteolytic cleavage of PARP-1 in CAL-27 (p=0.015), SCC-15
(p=0.006), FaDu (p=0.046), and SALTO (p=0.044) cells,
compared to DMSO-treated cells (Fig. 3a).
However, VIO-treated CAL-27 and SCC-15 showed a re-
duced expression of p53 compared to DMSO-treated cells
(p<0.05 and p<0.01, respectively). All carcinoma cell lines
showed the appearance of a lower molecular weight product,
which suggests that treatment with VIO is able to induce p53
degradation (Fig. 3b). Analysis by fluorescence microscopy
confirmed a decrease in p53 expression after VIO treatment
compared to DMSO-treated cells. There was no change in the
nuclear localization after VIO treatment (Fig. 3b).
VIO induces autophagy in HNC cells
Autophagy is considered a programmed cell death type II. The
formation of an Bautophagosome^ (vacuole membrane with a
double layer) is the marker of autophagy. The activation of the
autophagic process can be detected by the conversion of LC3-I
(a membrane protein autophagosome) in LC3-II, because the
amount of LC3-II clearly correlated with the number of
autophagosomes [30]. LC3-I (16 kDa) is a cytosolic protein,
while LC3-II (14 kDa), which is the conjugated form with
phosphatidylethanolamine (PE), is located in the membrane
autophagosome. To evaluate the effect of VIO on the induction
of autophagy, CAL-27, SCC-15, FaDu, and SALTO cells were
treated with VIO or DMSO at a concentration of 5–7.5 μM for
24 h. As shown in Fig. 3a, LC3-I and LC3-II were
constitutively expressed in DMSO-treated cells. After treatment
with VIO, the expression of LC3-II was significantly enhanced
compared to control cells (p<0.01). Therefore, our results indi-
cated that VIO treatment induced autophagy.
VIO inhibits mitogen-activated protein kinase signal
and the NF-κB transduction pathway in HNC cells
The mitogen-activated protein kinase (MAPK) pathway is
a signaling transduction pathway involved in cell growth
and is often aberrantly activated in tumors. To evaluate
whether VIO was able to inhibit MAPK activation, CAL-
27, SCC-15, FaDu, and SALTO cells were treated with
VIO or DMSO for 24 h and analyzed for the expression
and activation of ERK1 and ERK2. As shown in Fig. 4a,
treatment with VIO inhibited the level of phosphorylation
of ERK1 in FaDu (p=0.048), SCC-15 (p=0.014), and
SALTO (p=0.023) cells, compared to DMSO-treated cells.
VIO treatment inhibited phosphorylation of ERK2 in FaDu
(p=0.04), CAL-27 (p=0.045), SCC-15 (p=0.034), and
SALTO (p=0.006) cells.
The transcription factor NF-κB promotes the activation of
genes involved in inflammation, malignant transformation, tu-
mor invasion, and angiogenesis. Because the activation of this
transcription factor is associated with the process of carcinogen-
esis, its inhibition may be able to counteract neoplastic growth.
CAL-27, SCC-15, and FaDu cells were treated with VIO or
DMSO for 24 h and were then analyzed for the expression of
NF-κB. A representative experiment is shown in Fig. 4. Treat-
ment with VIO decreased the expression of NF-κB only in
Table 2 Effects of VIO on the
cell cycle of cell lines derived
from human tongue (CAL-27 and
SCC-15), pharynx (FaDu), or
mouse salivary gland (SALTO)
carcinomas and human non-
tumorigenic epithelial cell line
(MCF-10A)
Sub-G1a P value G0/G1 P value S phase P value G2/M P value
CAL-27 DMSO 3.98 74.53 4.88 16.34
VIO 10 74.43 <0.001 6.73 <0.001 5.71 NS 12.44 NS
VIO 5 10.98 <0.05 10.01 <0.001 34.11 <0.001 42.83 <0.001
SCC-15 DMSO 4.58 66.90 8.84 19.55
VIO 10 78.26 <0.01 7.74 <0.001 7.52 NS 6.41 <0.05
VIO 5 14.62 NS 37.51 <0.01 17.64 NS 30.16 <0.05
FADU DMSO 4.34 59.29 9.06 27.81
VIO 10 85.54 <0.001 8.02 <0.001 2.49 <0.05 4.11 <0.01
VIO 5 13.23 <0.05 54.05 NS 9.46 NS 23.78 NS
SALTO DMSO 9.45 57.88 13.32 19.87
VIO 10 67.97 <0.001 27.86 <0.001 2.34 <0.001 1.94 <0.01
VIO 5 33.13 <0.01 55.24 NS 7.66 <0.01 4.45 <0.01
MCF-10A DMSO 0.35 82.83 5.96 11.06
VIO 10 0.80 NS 79.87 NS 6.41 NS 13.21 NS
VIO 5 0.65 NS 81.92 NS 6.58 NS 11.11 NS
NS not significant
a Percentage of cells in the sub-G1, G0/G1, S, and G2/M phases were calculated using CellQuest software. The
data are representative of three experiments. VIO was used at 5 and 10 μM. Statistical significance of the effects
obtained with VIO was calculated versus those obtained in DMSO-treated cells
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SCC-15 cell (p<0.01; Fig. 4b). NF-κB functions as a transcrip-
tion factor, moving into its active form in the nucleus. To de-
termine if treatment with VIOwas able to affect translocation of
NF-κB to the nucleus, the localization of NF-κB was deter-
mined by immunofluorescence. NF-κBwas found to bemainly
localized in the nucleus in DMSO-treated FaDu, CAL-27, and
SCC-15 cells. In contrast, treatment with VIO induced an ac-
cumulation of NF-κB in the cytoplasm, thus indicating an in-
hibitory effect of VIO on NF-κB nuclear translocation
(Fig. 4b).
VIO induces ROS production in human HNC cells
To determine the effect of the compound at different con-
centrations (5, 10, and 20 μM) on intracellular ROS pro-
duction in human HNC, a DCF-DA assay was performed.
The effects of the compound were compared to those of
DMSO, and the results were expressed as the fluorescence
intensity (Table 3). VIO induced a significant increase in
ROS production at a concentration of 20 μM in CAL-27
cell (p<0.05) and at concentrations of 10 and 20 μM in
FaDu cell (p<0.05). Moreover, VIO induced a significant
dose-dependent ROS production at all concentrations in
SCC-15 ce l l (p < 0 . 05 , p < 0 . 05 , a nd p < 0 .001 ,
respectively; Table 3).
Delay of tumor growth in vivo by treatment with VIO
To evaluate whether the administration of VIO was able to
inhibit the growth of transplanted SALTO cell, groups of
BALB/c mice were treated by intratumoral injection with
VIO starting 3 weeks after a tumor cell transplant. DMSO
was used as a negative control. VIO reduced the mean
tumor volume compared to control mice 1 week after the
first VIO administration (157 vs 614 mm3; p<0.0001) and
maintained this decrease until 3 weeks following the be-
ginning of treatment (418 vs 3078 mm3, respectively;
p<0.0001). At this stage (6 weeks post-transplant),
DMSO-treated mice were sacrificed for exceeding tumor
volume, while all VIO-treated mice remained alive at this
Fig. 3 Effect of VIO on cell apoptosis and autophagy. a Assessment of
Bax, Bcl-2, procaspase-9, procaspase-8, caspase-8, cleavage of PARP-1
and LC3 levels by Western blotting in FaDu, CAL-27, SCC-15, and
SALTO cells treated for 24 h with VIO at 5–7.5 μM or with DMSO as
vehicle. Actin was used as an internal control. The intensities of the bands
obtained in two independent experiments were quantified using ImageJ
software after blot scanning, and the densitometric ratios between the Bax
and Bcl-2, between procaspase-9 and actin, and between cleaved and full
length PARP-1 are reported. Expression and densitometric quantization
of LC3-II in HNC cells after treatment with VIO using Western blotting
(p<0.01). bAssessment of p53 levels byWestern blotting in FaDu, CAL-
27, and SCC-15 cells treated for 24 h with VIO at 5–7.5 μM or with
DMSO as vehicle. Sub-cellular localization of p53 was analyzed by in-
direct immunofluorescence. After treatment, cells were fixed and incu-
bated with anti-p53 antibody. After two washes with PBS, cells were
incubated with the secondary Alexa Fluor-488-conjugated goat anti-
mouse IgG antibody. Nuclei were stained with Hoechst 33342. Original
magnification 400x
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time. Two VIO-treated mice were sacrificed 9 weeks after
treatment, while four of these were still alive. All VIO-
treated mice were sacrificed between weeks 12 and 13 after
treatment. One VIO-treated mouse was still alive after
30 weeks with stable disease (320 mm3) (Fig. 5). VIO
prolonged the median survival time compared to DMSO
(12.5 vs 3 weeks) (p=0.0005). Overall, the risk of devel-
oping tumors in DMSO-treated mice was 38.79 times
greater than in the VIO-treated mice. Thus, our results sug-
gest that VIO is able to significantly delay tumor growth
and prolong median survival in comparison to DMSO
(Table 4).
Discussion
Cancer chemoprevention employs natural or synthetic com-
pounds to prevent, arrest, or reverse carcinogenesis [18]. The
use of bacteria for the treatment of certain forms of cancer has
been utilized since the early part of the last century [31]. In
recent decades, compounds derived from bacteria have been
tested for their anti-cancer activity [19, 20]. This involves the
use of attenuated bacterial strains, spores, or bacterial strains
engineered to express foreign genes. Novel approaches in-
clude the use of bacterial products such as proteins, enzymes,
or secondary metabolites such as pigments, which can cause
Fig. 4 Effect of VIO on pro-survival signaling proteins. a ERK1/ERK2
phosphorylation status in treated HNC cell lines. Western blotting was
performed on VIO-treated (5–7.5 μM) or DMSO-treated cells for 24 h.
The levels of phosphorylated ERK1/ERK2 were compared with those of
the total ERK proteins, and the ratios are reported. b Expression and
densitometric quantization of NF-κB in HNC cells after treatment with
VIO by Western blotting. Inhibition of nuclear translocation of NF-κB
after treatment with VIO in HNC cells. After treatment, cells were fixed
and incubated with the anti-NF-κB antibody. Alexa Fluor-488-
conjugated goat anti-mouse IgG antibody was used as secondary anti-
body. Nuclei were stained with Hoechst 33342. Original magnification
400x
Table 3 Effects of VIO on the intracellular ROS production in cell lines derived from HNC cells of the tongue (CAL-27 and SCC-15) or pharynx
(FaDu)
CAL-27 SCC-15 FaDu
Mean±SDa P value Mean±SD P value Mean±SD P value
DMSO 4057±16 4048±4 4666±254
VIO 5 3891±158 4120±4 <0.05 4767±201
VIO 10 4097±160 4143±25 <0.05 5499±124 <0.05
VIO 20 4381±66 <0.05 4815±40 <0.001 5593±156 <0.05
a The results are reported as the mean of the fluorescence intensity±SD (standard deviation) values from three experiments performed in triplicate. VIO
was used at 5, 10, and 20 μM. Statistical significance of the effects obtained with VIO was calculated versus those obtained with DMSO
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growth inhibition, cell cycle arrest, or the apoptosis of tumor
cells [32]. Natural pigments can be purified from ores, insects,
plants, and microbes. Among the others, bacteria have great
potential to produce diverse pigments. Bacterial pigments can
be easily produced and purified, and several strategies have
been developed to improve the yield and quality of pigment
production. Among the molecules produced by bacteria are
carotenoids, melanins, flavins, phenazines, quinones, bacte-
riochlorophylls, monascins, violacein, and prodigiosin [33].
Among the others, prodigiosins and VIO have been demon-
strated to have anti-cancer activity [32].
VIO (3-[1,2-dihydro-5-(5-hydroxy-1H-indol-3-yl)-2-oxo-
3H-pyrrol-3-ylidene]-1,3-dihydro-2H-indol-2-one), an
indole-derived purple-colored pigment, produced by a limited
number of Gram-negative bacteria species, including
C. violaceum and J. lividum [9], has been shown to display
anti-cancer activity by interfering with survival signaling path-
ways in different cancer models [10–14].
HNC represents the sixth most common cancer worldwide
and mainly involves the larynx, pharynx, oral cavity, and
tongue [15, 16]. The current strategies to cure HNC have
limited efficacy and documented toxicity, and HNC remains
one of the most fatal cancers worldwide [17]. The prognosis of
HNC is discouraging. Local tumor progression leads to mor-
bidity and even death in the majority of patients. Chemother-
apy regimens used in these patients show very significant side
effects and a poor quality of life [34].
Intratumoral delivery of cancer therapeutics promises to be
a good route of administration for such agents in easily acces-
sible tumors. Several pre-clinical and phase I and phase II
clinical trials are employing intratumoral delivery to deliver
different therapeutics such as drugs, viral-based cancer vac-
cines, immune cell-based vaccines, cytokines, DNA, bacterial
products, and natural compounds to the tumor site [28,
35–39]. An intratumoral route of administration is able to
prevent the occurrence of systemic side effects and makes
the therapeutic agents directly available at the tumor site,
allowing for the highest concentration close to tumor cells.
In this study, we provided evidence that VIO inhibits
HNC cell proliferation and induces apoptosis in HNC cell
lines. Our results indicate that VIO is able to inhibit the
growth of different cell lines in a dose-dependent manner.
Moreover, treatment with VIO induced a dose-dependent
increase in the percentage of cells in the sub-G1 phase, an
increased expression of Bax, a decreased expression of
Bcl-2 and PARP-1 cleavage. VIO treatment was able to
activate both the intrinsic and extrinsic apoptotic path-
ways, as demonstrated by the cleavage of procaspase-8
and the decreased expression of procaspase-9. It has been
previously demonstrated that VIO is able to induce the
activation of both the intrinsic and extrinsic apoptotic path-
ways in colorectal cancer and leukemia cells [13, 40]. VIO
did not affect cell survival of MCF-10A and HaCaT at the
concentration of 1–2.5 to 5–10 μM after 24, 48, or 72 h of
treatment. However, although significant differences in
cell survival between HNC and MCF-10A and HaCaT cells
were observed at the 15 μM concentration, VIO affected to
some extent MCF-10A and HaCaT cell survival at this
dose. The distinct VIO effect on cancer and non-
tumorigenic cell lines might be due to VIO-mediated inhi-
bition of specific signaling transduction pathways which
are aberrantly activated in cancer cells.
Fig. 5 Delay of in vivo tumor growth by treatment with VIO. Groups of BALB/c mice were treated with VIO 3 weeks after SALTO tumor cell
implantation. Differences in the tumor volumes and the mean survival time among the treated mice are reported
Table 4 Comparison of mice survival by log-rank (Mantel-Cox) test
Variable Contrast Hazard ratio 95 % hazard ratio confidence limits P value Median survival (weeks)
Lower Upper
Treatment Violacein vs DMSO 38.76 5.01 299.8 0.0005 12.5 vs 3
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It has been shown that the activation of caspase-8 by VIO is
mediated by direct activation of the tumor necrosis factor re-
ceptor 1 (TNFR1) in leukemia cells and that HNC cell lines
express TNFR1 [7, 41]. Thus, the cleavage of caspase-8 in
HNC cells upon VIO treatment may be mediated by the acti-
vation of TNFR1. It has been shown that treatment with VIO
induces the production of ROS in colon carcinoma and
Ehrlich’s ascites cell lines [10–12]. We demonstrated that VIO
treatment of HNC cells induces an increase in ROS production.
ROS are known to trigger the intrinsic apoptotic cascade via
interactions with proteins of the mitochondrial permeability
transition complex [42, 43]. The p53 protein activates DNA
repair, cell cycle arrest, or apoptosis in response to DNA dam-
age [44]. In the HNC cell lines analyzed, treatment with VIO
reduced the expression of p53, with the appearance of a low
molecular weight product, indicative of a degradation process.
Accordingly, p53, after the activation of the intrinsic pathways
of apoptosis, may be ubiquitinated and degraded.
During autophagy, the ubiquitin-like LC3 protein or
ATG8 is converted to LC3-I and LC3-II, the latter being
a specific marker for the formation of the autophagosome
[30]. Treatment with VIO was able to induce increased
expression of LC3-I and LC3-II in all cell lines analyzed,
thus suggesting a possible role for autophagy in the inhi-
bition of HNC cell growth. Bcl-2 is a key regulator of
apoptosis and autophagy. It has been shown that Bcl-2
prevents apoptosis by inhibiting pro-apoptotic proteins,
as Bax, and inhibits autophagy by binding to Beclin1
[45]. Beclin1 is a Bcl-2-interacting protein that promotes
autophagy and is inhibited by binding with Bcl-2. Thus,
the decreased expression of Bcl-2 upon VIO treatment in
HNC cell lines could make Beclin1 available to promote
autophagy. To our knowledge, this is the first report dem-
onstrating VIO-mediated autophagy in cancer cells.
Previous studies showed that HNC cell lines overex-
press the ErbB receptor family, which in turn plays an
essential role in the mechanisms of carcinogenesis of head
and neck tumors [46]. The MAP kinases ERK1/2 are in-
volved in the transduction pathways triggered by ErbB
receptors. Their role as survival factors in several tumors
is associated with their ability to stimulate nuclear translo-
cation and activation of the transcription factor NF-κB
[47]. The NF-κB pathway is often aberrantly activated dur-
ing the development and progression of HNC [47, 48].
Previous studies have shown that VIO, while having no
effect on the MAPK pathway, reduces the activity of
NF-κB in colorectal cancer cell lines or activates NF-κB
in leukemia cells through the activation of TNFR1 [7, 13].
Our results demonstrated that VIO treatment was able to
inhibit ERK1/2 phosphorylation and NF-κB nuclear trans-
location in HNC cells. It was shown that NF-κB is in-
volved in inflammatory processes and in the transforma-
tion, survival, and invasiveness of HNC and that the ability
of different chemotherapeutic compounds to inhibit NF-κB
activation is the basis of the therapeutic effects of these
compounds [49–51]. The VIO-mediated inhibition of
ERK1/2 may be responsible for the significant accumula-
tion of NF-κB in the cytoplasm and may induce cell death
and the inhibition of cell proliferation. In addition, the ac-
tivation of NF-κB induced the expression of the anti-
apoptotic Bcl-2 family genes [52]. Thus, NF-κB inhibition
may initiate the apoptotic and autophagic processes via
Bcl-2 downregulation.
It has been shown that intraperitoneally administered VIO
showed anti-proliferative activity against subcutaneous
transplanted HNC in nude mice in vivo [53].
Because a limited number of animal studies are available
on the anti-cancer effects of VIO, we evaluated the in vivo
effects of intratumoral administration of VIO in hindering the
growth of transplanted Neu-overexpressing BALB-neuT
SALTO in BALB/c mice.
We demonstrated that VIO induced SALTO apoptosis,
cell growth inhibition, and inhibition of ERK1/2 activation
in vitro. Then, we performed an in vivo study. VIO was
intratumorally administered 3 weeks after a SALTO tumor
cell challenge. Our results demonstrated that VIO was able
to significantly delay tumor growth and prolong median
survival in agreement with our in vitro observations. In
addition, it has been reported that the administration of
VIO was safe, since no alteration of hematology and bio-
chemistry parameters (ALT, AST, and creatinine levels)
has been observed in BALB/c mice treated with daily i.p.
doses of VIO up to 1 mg/kg for 35 days. Furthermore, VIO
did not cause hematotoxicity, renal, and hepatotoxicity in
mice [11]. Few other papers have intraperitoneally admin-
istered VIO in vivo [11, 53]. This is the first time that VIO
has been intratumorally administered. Our findings may
play a significant role in planning cancer therapy protocols
using VIO or other bacteria derivatives for the treatment of
salivary gland tumors and other accessible tumors by
intratumoral administration.
Taken together, our results indicate that the treatment of
HNC cells with VIO may be useful in the inhibition of
in vivo and in vitro cancer cell growth. Because the mo-
lecular mechanisms of the action of VIO involve the acti-
vation of specific signaling transduction pathways, which
vary depending on the cell type, additional studies per-
formed both in vitro and in vivo will be necessary to fully
define the anti-cancer therapeutic potential of this
compound.
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